ABOS
NASDAQ · Biotechnology
Acumen Pharmaceuticals Inc
$2.67
-0.10 (-3.61%)
Open$2.77
Previous Close$2.77
Day High$2.83
Day Low$2.65
52W High$3.60
52W Low$1.10
Volume—
Avg Volume467.2K
Market Cap170.46M
P/E Ratio—
EPS$-1.86
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+732.2% upside
Current
$2.67
$2.67
Target
$22.22
$22.22
$18.81
$22.22 avg
$35.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.13M | 32.40M | 26.28M |
| Net Income | 3.79M | 3.97M | 2.79M |
| Profit Margin | 11.8% | 12.2% | 10.6% |
| EBITDA | 5.50M | 6.39M | 4.32M |
| Free Cash Flow | 1.86M | 2.43M | 2.61M |
| Rev Growth | +20.9% | +8.5% | +2.1% |
| Debt/Equity | 0.36 | 0.35 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |